Assouline · Critical care medicine 2021 · systematic review and meta-analysis of randomized controlled trials · n=8 trials (1,335 patients)

Thiamine, Ascorbic Acid, and Hydrocortisone As a Metabolic Resuscitation Cocktail in Sepsis: A Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis.

Cited 56 times in the scientific literature.

Level 1 - systematic review of randomized trials

Systematic review and meta-analysis of randomized controlled trials

PubMed 34582409 · doi:10.1097/CCM.0000000000005262 · record verified 2026-08-30

What was done

Authors conducted a systematic review and meta-analysis searching PubMed, Embase, and Cochrane databases through March 2021. They included randomized controlled trials evaluating a combination of thiamine, ascorbic acid, and hydrocortisone versus standard care or placebo in adult ICU patients with sepsis or septic shock. The primary endpoint was change in Sequential Organ Failure Assessment (SOFA) score within 72 hours. Secondary outcomes included vasopressor duration, ICU mortality, and a composite renal endpoint (KDIGO stage 3 acute kidney injury or need for renal replacement therapy).

What was found

Eight randomized controlled trials with 1,335 patients were analyzed. For the 72-hour SOFA score change (8 RCTs, n = 1,253), the median of mean improvement was -3.2 in the intervention group compared to -1.8 in controls, yielding a weighted mean difference of -0.82 points (95% CI, -1.15 to -0.48). Vasopressor duration was significantly reduced in the intervention group across 6 RCTs (exact values not reported in abstract). There was no significant difference in ICU mortality or the renal composite outcome across 7 RCTs.

Why it matters

Early observational studies suggested dramatic benefits from this metabolic cocktail, but this pooled RCT evidence demonstrates that the small physiological improvements do not translate into clinical survival or renal benefits in sepsis.

Limits

The abstract does not provide exact effect estimates, confidence intervals, or p-values for mortality, vasopressor duration, or renal failure. The overall pooled sample size across 8 trials is relatively modest (1,335 patients), and the clinical significance of a 0.82-point SOFA reduction is minimal.

Cited by